Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pbf-999. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A known ✓ | Q9Y233 | 15/20 | 1.00 |
| ▸ | ADORA2A known ✓ | P29274 | 3/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905187 | 0.80 | PDE10A (0.67) | PDE10AADORA2A | |
| SCHEMBL14672427 | 0.80 | ADORA2A (0.67) | PDE10AADORA2A | |
| SCHEMBL15905211 | 0.79 | PDE10A (1.00) | PDE10AADORA2APDE4A | |
| SCHEMBL15905179 | 0.76 | PDE10A (1.00) | PDE10AADORA2A | |
| SCHEMBL15905011 | 0.76 | PDE10A (0.74) | PDE10AADORA2A | |
| SCHEMBL15905134 | 0.75 | PDE10A (0.67) | PDE10AADORA2A | |
| SCHEMBL15904768 | 0.74 | PDE10A (0.69) | PDE10A | |
| SCHEMBL15905374 | 0.74 | PDE10A (1.00) | PDE10AADORA2A | |
| SCHEMBL28042559 | 0.74 | PDE10A (0.58) | PDE10AADORA2APDE4APDE4B | |
| SCHEMBL15905097 | 0.72 | PDE10A (0.68) | PDE10AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | claimed |
| WO-2025051110-A1 | COMBINATIONS TREATMENTS OF DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND OTHER THERAPIES | INSILICO MEDICINE IP LIMITED (CN) | 2025-03-13 | — | — | WO | claimed |
| EP-3743418-B1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2024-07-31 | — | — | EP | claimed |
| US-9447095-B2 | Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10) | PALOBIOFARMA S.L. (ES) | 2016-09-20 | — | — | US | claimed |
| EP-2948443-B1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA SL (ES) | 2016-08-31 | — | — | EP | claimed |
| EP-2948443-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-12-02 | — | — | EP | claimed |
| US-20150336953-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-11-26 | — | — | US | claimed |
| WO-2014114695-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L (ES) | 2014-07-31 | — | — | WO | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2024249894-A9 | BIOMARKERS FOR PREDICTING CANCER TREATMENT EFFICACY | ARCUS BIOSCIENCES, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720679-A2 | BIOMARKERS FOR PREDICTING CANCER TREATMENT EFFICACY | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-3490565-B1 | AZETIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-9447095-B2 | Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10) | PALOBIOFARMA S.L. (ES) | 2016-09-20 | — | — | US | disclosed |
| EP-2948443-B1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA SL (ES) | 2016-08-31 | — | — | EP | disclosed |
| EP-2948443-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-12-02 | — | — | EP | disclosed |
| US-20150336953-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L. (ES) | 2015-11-26 | — | — | US | disclosed |
| WO-2014114695-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PALOBIOFARMA S.L (ES) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116868-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBLC, CBL | PDE10A 4216/4885ADORA2A 4218/4885PDE4A 4693/4885 |
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | CCR1, CXCR2, CCR2 | PDE10A 1388/4885ADORA2A 382/4885PDE4A 863/4885 |
| US-20150336953-A1 | NEW PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS (PDE-10) | PDE12, PDE5A, PDE10A | PDE10A 3/4885ADORA2A 152/4885PDE4A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.